Skip to main content
Top
Published in: BMC Nephrology 1/2018

Open Access 01-12-2018 | Case report

Pulmonary lymphangioleimyomatosis and systemic lupus erythematosus in a menopausal woman

Authors: Hong Hong, Ruiheng Yang, Xiuzhen Li, Mengjun Wang, Zhongchao Ma

Published in: BMC Nephrology | Issue 1/2018

Login to get access

Abstract

Background

Pulmonary lymphangioleimyomatosis (PLAM) is a rare disease involving lung. PLAM primarily affects young women, a characteristic it shares with systemic lupus erythematosus (SLE). Estrogen has long been assumed to play an important role both in PLAM and SLE. We report a menopausal woman, who was found to have PLAM 1 year after she was diagnosed with SLE. Her chest radiograph was normal in the early phase of SLE.

Case presentation

A 52-year-old Chinese woman was referred to our hospital in August 2014 because of swelling in both legs. She also reported a malar rash and intermittent generalized arthralgia. Laboratory examination showed leukopenia. Her serum albumin level was 23 g/L; 24-h urinary protein excretion was 5.3 g. She tested positive for anti-Smith (Sm) antibody and anti-SS-A antibody. Renal biopsy indicated Class V + IV(G)-A lupus nephritis (LN). The condition of SLE and LN improved on a regime of tapering prednisolone and intermittent intravenous cyclophosphamide therapy until 1 year later when she developed exertional dyspnea accompanied with frequent cough. Thoracic computed tomography revealed numerous well-defined cysts and the diagnosis of PLAM was confirmed by lung biopsy. In the follow-up period, the patient continued to be on prednisolone and mycophenolate mofetil for the treatment of SLE, but only agreed to receive symptomatic treatment for PLAM. One year after the diagnosis of PLAM, during which time the SLE was stable, she died of respiratory failure and cor pulmonale.

Conclusion

We report a patient with coexisting SLE and PLAM, who was treated with immunosuppressive therapy. SLE was stable but PLAM was not improved. Although the coexistence of SLE and PLAM might be a coincidence, the occurrence of these two diseases in a menopausal woman may warrant further mechanistic exploration.
Literature
1.
go back to reference Meraj R, Wikenheiser-Brokamp KA, Young LR, et al. Lymphangioleiomyomatosis:new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med. 2012;33(5):486–97.CrossRef Meraj R, Wikenheiser-Brokamp KA, Young LR, et al. Lymphangioleiomyomatosis:new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med. 2012;33(5):486–97.CrossRef
2.
go back to reference Ando K, Tobino K, Kufihara M, et al. Quantitative CT analysis of small pulmonary vessels in lymphangloleiomyomatosis. Eur J Radiol. 2012;81(12):3925–30.CrossRef Ando K, Tobino K, Kufihara M, et al. Quantitative CT analysis of small pulmonary vessels in lymphangloleiomyomatosis. Eur J Radiol. 2012;81(12):3925–30.CrossRef
3.
go back to reference Henske EP, McCormack FX. Lymphangioleiomyomatosis-a wolf in sheep’s clothing. Clin Invest. 2012;122(11):3807–16.CrossRef Henske EP, McCormack FX. Lymphangioleiomyomatosis-a wolf in sheep’s clothing. Clin Invest. 2012;122(11):3807–16.CrossRef
4.
go back to reference Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med. 1990;323(18):1254–60.CrossRef Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med. 1990;323(18):1254–60.CrossRef
5.
go back to reference Lam B, Ooi GC, Wong MP, et al. Extrapulmonary presentation of asymptomatic pulmonary lymphangioleiomyomatosis. Respirology. 2003;8(4):544–7.CrossRef Lam B, Ooi GC, Wong MP, et al. Extrapulmonary presentation of asymptomatic pulmonary lymphangioleiomyomatosis. Respirology. 2003;8(4):544–7.CrossRef
6.
go back to reference Xucheng ZH, Travis WD. Pulmonary Lymphangioleiomyomatosis. Arch Pathol Lab Med. 2010;134(12):1823–8. Xucheng ZH, Travis WD. Pulmonary Lymphangioleiomyomatosis. Arch Pathol Lab Med. 2010;134(12):1823–8.
7.
go back to reference McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, AM T-DS, Lee HS, Krischer JP, Trapnell BC, National Institutes of Health Rare Lung Diseases Consortium, MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–606. https://doi.org/10.1056/NEJMoa1100391. CrossRefPubMedPubMedCentral McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, AM T-DS, Lee HS, Krischer JP, Trapnell BC, National Institutes of Health Rare Lung Diseases Consortium, MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–606. https://​doi.​org/​10.​1056/​NEJMoa1100391.​ CrossRefPubMedPubMedCentral
8.
go back to reference Schiavina M, Contini P, Fabiani A, et al. Efficacy of hormonal manipulation in lymphangioleiomyomatosis: a 20-year-experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24(1):39–50.PubMed Schiavina M, Contini P, Fabiani A, et al. Efficacy of hormonal manipulation in lymphangioleiomyomatosis: a 20-year-experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24(1):39–50.PubMed
9.
go back to reference Mc Cormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133(2):507–16.CrossRef Mc Cormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133(2):507–16.CrossRef
10.
go back to reference Mark M. Hammer, Anup S. Shetty, Elizabeth F. Sheybani, Sanjeev Bhalla. Diseases and syndromes that affect the lungs and the kidneys: a radiologic review. Curr Probl Diagn Radiol. 2017;46(3):216–24. Mark M. Hammer, Anup S. Shetty, Elizabeth F. Sheybani, Sanjeev Bhalla. Diseases and syndromes that affect the lungs and the kidneys: a radiologic review. Curr Probl Diagn Radiol. 2017;46(3):216–24.
11.
go back to reference Branley HM. Systemic diseases and the lung. Medicine. 2012;40(6):305–9. Respiratory Disorders: Part 3 of 3CrossRef Branley HM. Systemic diseases and the lung. Medicine. 2012;40(6):305–9. Respiratory Disorders: Part 3 of 3CrossRef
12.
go back to reference Cheema S. QuismorioFP.Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med. 2000;6:424–9.CrossRef Cheema S. QuismorioFP.Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med. 2000;6:424–9.CrossRef
13.
go back to reference Zhang Z, Chen L. The association between fluid balance and mortality in patients with ARDS was modified by serum potassium levels: a retrospective study. PeerJ. 2015 Feb 10;3:e752.CrossRef Zhang Z, Chen L. The association between fluid balance and mortality in patients with ARDS was modified by serum potassium levels: a retrospective study. PeerJ. 2015 Feb 10;3:e752.CrossRef
14.
go back to reference Zhang Z, Chen L, Ni H. The effectiveness of corticosteroids on mortality in patients with acute respiratory distress syndrome or acute lung injury: a secondary analysis. Sci Rep. 2015;5:17654.CrossRef Zhang Z, Chen L, Ni H. The effectiveness of corticosteroids on mortality in patients with acute respiratory distress syndrome or acute lung injury: a secondary analysis. Sci Rep. 2015;5:17654.CrossRef
Metadata
Title
Pulmonary lymphangioleimyomatosis and systemic lupus erythematosus in a menopausal woman
Authors
Hong Hong
Ruiheng Yang
Xiuzhen Li
Mengjun Wang
Zhongchao Ma
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2018
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-018-0889-2

Other articles of this Issue 1/2018

BMC Nephrology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.